Chronic Myeloproliferative Disorders Completed Phase 2 Trials for Aldesleukin (DB00041)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00002504Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic CancerTreatment
NCT00003408Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With CancerTreatment